Table 2.
Follow-Up Time and rwToT With Pembrolizumab for Patients With Advanced Squamous NSCLC Treated With First-Line Pembrolizumab-Chemotherapy, Overall and by PD-L1 Expression
| Characteristics | All Patients N = 364 |
PD-L1 Expression |
||
|---|---|---|---|---|
| ≥1% n = 172 | <1% n = 94 | Unknown n = 98 | ||
| Theoretical follow-up, median (range), moa | 26.2 (17.1–36.0) | 26.0 (17.1–35.9) | 27.0 (17.1–35.5) | 25.8 (17.1–36.0) |
| Patient follow-up, median (range), moa | 17.1 (<0.1–35.8) | 17.1 (<0.1–35.8) | 17.3 (<0.1–35.0) | 14.1 (<0.1–35.8) |
| Pembrolizumab doses, median (range) | 9 (1–49) | 9 (1–47) | 9 (1–49) | 9 (1–49) |
| Discontinued pembrolizumab, n (%) | 289 (79.4) | 136 (79.1) | 74 (78.7) | 79 (80.6) |
| rwToT, median (95% CI), mo | 6.5 (5.6–7.6) | 6.9 (5.3–8.3) | 5.8 (4.6–8.3) | 6.3 (4.2–8.2) |
| On-treatment rate, % (95% CI)b | ||||
| At 12 mo | 29.3 (24.6–34.2) | 28.6 (21.9–35.7) | 31.5 (22.2–41.2) | 28.6 (19.9–37.9) |
| At 24 mo | 15.9 (11.8–20.6) | 16.3 (10.6–23.2) | 15.8 (8.4–25.2) | 15.3 (7.9–25.1) |
| Restricted mean rwToT (95% CI), mo | ||||
| Restricted to 12 mo | 6.7 (6.3–7.2) | 6.8 (6.2–7.5) | 6.8 (6.0–7.7) | 6.5 (5.6–7.4) |
| Restricted to 24 mo | 9.6 (8.7–10.5) [Weibull] | 9.7 (8.5–11.1) [Weibull] | 9.8 (8.3–11.7) [log logistic] | 9.1 (7.5–11.0) [Weibull] |
CI, confidence interval; mo, month; PD-L1, programmed death-ligand 1; rwToT, real-world time on treatment.
a
Theoretical follow-up was defined as the duration of follow-up from first-line therapy initiation to database cutoff (October 31, 2021). Patient follow-up was defined as time from first-line therapy initiation to the date of death or data cutoff, whichever occurred first.
b
On-treatment rates were based on Kaplan-Meier estimates.